MA42455B1 - Nouveau composé hétérocyclique, procédé de préparation associé et composition pharmaceutique le comprenant - Google Patents
Nouveau composé hétérocyclique, procédé de préparation associé et composition pharmaceutique le comprenantInfo
- Publication number
- MA42455B1 MA42455B1 MA42455A MA42455A MA42455B1 MA 42455 B1 MA42455 B1 MA 42455B1 MA 42455 A MA42455 A MA 42455A MA 42455 A MA42455 A MA 42455A MA 42455 B1 MA42455 B1 MA 42455B1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical composition
- heterocyclic compound
- preparation process
- novel heterocyclic
- associated preparation
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 102000003960 Ligases Human genes 0.000 abstract 1
- 108090000364 Ligases Proteins 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne un composé hétérocyclique ayant une nouvelle structure qui peut être utilisé dans la prévention ou le traitement de maladies provoqués par une anomalie dans une activité prs (prolyl-arnt synthétase), un procédé de préparation associé et une composition pharmaceutique le comprenant.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150080722A KR102277538B1 (ko) | 2015-06-08 | 2015-06-08 | 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
| EP16807756.8A EP3303320B1 (fr) | 2015-06-08 | 2016-06-07 | Nouveau composé hétérocyclique, procédé de préparation associé et composition pharmaceutique le comprenant |
| PCT/KR2016/005999 WO2016200116A1 (fr) | 2015-06-08 | 2016-06-07 | Nouveau composé hétérocyclique, procédé de préparation associé et composition pharmaceutique le comprenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42455B1 true MA42455B1 (fr) | 2020-02-28 |
Family
ID=57504227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA42455A MA42455B1 (fr) | 2015-06-08 | 2016-06-07 | Nouveau composé hétérocyclique, procédé de préparation associé et composition pharmaceutique le comprenant |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10011586B2 (fr) |
| EP (1) | EP3303320B1 (fr) |
| JP (1) | JP6605624B2 (fr) |
| KR (1) | KR102277538B1 (fr) |
| CN (1) | CN107428725B (fr) |
| AU (1) | AU2016275210B2 (fr) |
| BR (1) | BR112017020053B1 (fr) |
| CA (1) | CA2977752C (fr) |
| ES (1) | ES2769279T3 (fr) |
| HR (1) | HRP20200104T8 (fr) |
| HU (1) | HUE047537T2 (fr) |
| MA (1) | MA42455B1 (fr) |
| MY (1) | MY172656A (fr) |
| NZ (1) | NZ735032A (fr) |
| PH (1) | PH12017501735B1 (fr) |
| PL (1) | PL3303320T3 (fr) |
| PT (1) | PT3303320T (fr) |
| RS (1) | RS59787B1 (fr) |
| RU (1) | RU2675375C1 (fr) |
| SI (1) | SI3303320T1 (fr) |
| WO (1) | WO2016200116A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY174343A (en) | 2014-06-23 | 2020-04-09 | Dae Woong Pharma | Novel heterocyclic compound |
| AR110963A1 (es) | 2017-02-07 | 2019-05-22 | Dae Woong Pharma | Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende |
| WO2023113540A1 (fr) * | 2021-12-17 | 2023-06-22 | 주식회사 대웅제약 | Nouveau sel d'addition d'acide et forme cristalline de (2r,3s)-2-(3-(4,5-dichloro-1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol |
| JP2025529524A (ja) * | 2022-10-12 | 2025-09-04 | デウン ファーマシューティカル カンパニー リミテッド | 腎臓炎の予防または治療用薬学的組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59504622D1 (de) * | 1994-10-31 | 1999-02-04 | Merck Patent Gmbh | Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren |
| AU2009282480B2 (en) * | 2008-08-11 | 2015-05-07 | Children's Medical Center Corporation | Halofuginone analogs for inhibition of tRNA synthetases and uses thereof |
| US20120058133A1 (en) * | 2009-02-19 | 2012-03-08 | President And Fellows Of Harvard College | Inhibition of trna synthetases and therapeutic applications thereof |
| US10155742B2 (en) | 2012-01-13 | 2018-12-18 | President And Fellows Of Harvard College | Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions |
| WO2014100716A1 (fr) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| RU2016114498A (ru) * | 2013-10-24 | 2017-11-29 | Джорджтаун Юниверсити | Способы и композиции для лечения раковых заболеваний |
| MY174343A (en) * | 2014-06-23 | 2020-04-09 | Dae Woong Pharma | Novel heterocyclic compound |
-
2015
- 2015-06-08 KR KR1020150080722A patent/KR102277538B1/ko active Active
-
2016
- 2016-06-07 HR HRP20200104TT patent/HRP20200104T8/hr unknown
- 2016-06-07 US US15/556,352 patent/US10011586B2/en active Active
- 2016-06-07 MY MYPI2017703542A patent/MY172656A/en unknown
- 2016-06-07 WO PCT/KR2016/005999 patent/WO2016200116A1/fr not_active Ceased
- 2016-06-07 EP EP16807756.8A patent/EP3303320B1/fr active Active
- 2016-06-07 CA CA2977752A patent/CA2977752C/fr active Active
- 2016-06-07 PT PT168077568T patent/PT3303320T/pt unknown
- 2016-06-07 ES ES16807756T patent/ES2769279T3/es active Active
- 2016-06-07 BR BR112017020053-8A patent/BR112017020053B1/pt active IP Right Grant
- 2016-06-07 AU AU2016275210A patent/AU2016275210B2/en active Active
- 2016-06-07 HU HUE16807756A patent/HUE047537T2/hu unknown
- 2016-06-07 NZ NZ735032A patent/NZ735032A/en unknown
- 2016-06-07 SI SI201630590T patent/SI3303320T1/sl unknown
- 2016-06-07 MA MA42455A patent/MA42455B1/fr unknown
- 2016-06-07 RU RU2017133524A patent/RU2675375C1/ru active
- 2016-06-07 JP JP2017560322A patent/JP6605624B2/ja active Active
- 2016-06-07 PH PH1/2017/501735A patent/PH12017501735B1/en unknown
- 2016-06-07 PL PL16807756T patent/PL3303320T3/pl unknown
- 2016-06-07 RS RS20200049A patent/RS59787B1/sr unknown
- 2016-06-07 CN CN201680016550.XA patent/CN107428725B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20200104T8 (hr) | 2021-02-19 |
| ES2769279T3 (es) | 2020-06-25 |
| CA2977752C (fr) | 2020-03-31 |
| CN107428725B (zh) | 2020-01-03 |
| US20180044322A1 (en) | 2018-02-15 |
| CN107428725A (zh) | 2017-12-01 |
| AU2016275210A1 (en) | 2017-09-21 |
| KR20160144213A (ko) | 2016-12-16 |
| WO2016200116A1 (fr) | 2016-12-15 |
| RU2675375C1 (ru) | 2018-12-19 |
| PL3303320T3 (pl) | 2020-06-29 |
| NZ735032A (en) | 2019-05-31 |
| HUE047537T2 (hu) | 2020-05-28 |
| RS59787B1 (sr) | 2020-02-28 |
| SI3303320T1 (sl) | 2020-02-28 |
| PH12017501735B1 (en) | 2022-11-16 |
| MY172656A (en) | 2019-12-09 |
| HRP20200104T1 (hr) | 2020-04-03 |
| PH12017501735A1 (en) | 2018-03-12 |
| KR102277538B1 (ko) | 2021-07-14 |
| EP3303320B1 (fr) | 2020-01-01 |
| PT3303320T (pt) | 2020-02-03 |
| JP6605624B2 (ja) | 2019-11-13 |
| BR112017020053A2 (pt) | 2018-06-05 |
| CA2977752A1 (fr) | 2016-12-15 |
| BR112017020053B1 (pt) | 2023-01-31 |
| EP3303320A4 (fr) | 2018-12-05 |
| AU2016275210B2 (en) | 2018-07-26 |
| US10011586B2 (en) | 2018-07-03 |
| EP3303320A1 (fr) | 2018-04-11 |
| JP2018515558A (ja) | 2018-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201792047A1 (ru) | Новые соединения | |
| EA201990019A1 (ru) | Соединения и композиции для подавления активности shp2 | |
| EA201990665A1 (ru) | Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака | |
| EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| EA201791867A1 (ru) | Бициклические гетероциклы как ингибиторы fgfr4 | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| CO2019007834A2 (es) | Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende | |
| MX383213B (es) | Inhibidores de tirosina-cinasas | |
| EA201791874A1 (ru) | Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение | |
| MA41251B1 (fr) | Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk | |
| EA201691514A1 (ru) | Соединения | |
| MY197440A (en) | Heteroamatic compounds as btk inhibitors | |
| EA201791259A1 (ru) | Производные пиперидина в качестве ингибиторов hdac1/2 | |
| MA41238B1 (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
| EP3539951A4 (fr) | Nouveau composé de pyrimidine, son procédé de préparation et composition pharmaceutique le contenant en tant que principe actif pour la prévention ou le traitement du cancer et des maladies inflammatoires | |
| EA202091372A1 (ru) | Производное пирроло(пиразоло)пиримидина в качестве ингибитора lrrk2 | |
| MA47736B1 (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 | |
| PH12021551280A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| PH12021550269A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| MX2017011277A (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
| MX2018010801A (es) | Derivados de acido a-truxilico y composiciones farmaceuticas de los mismos. | |
| EA201790699A1 (ru) | Стабилизированные производные адреномедуллина и их применение | |
| PH12016502568A1 (en) | Novel heterocyclic compound | |
| PH12017501735B1 (en) | Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same |